These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17363184)

  • 41. Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas.
    Kelly JD; Dai J; Eschwege P; Goldberg JS; Duggan BP; Williamson KE; Bander NH; Nanus DM
    Br J Cancer; 2004 Jul; 91(1):164-70. PubMed ID: 15188008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
    Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
    Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential therapeutic applications of oblimersen in CLL.
    Koziner B
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):32-8. PubMed ID: 15651175
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypothesis links emergence of chloroquine-resistant malaria and other intracellular pathogens and suggests a new strategy for treatment of diseases caused by intracellular parasites.
    Parris GE
    Med Hypotheses; 2004; 62(3):354-7. PubMed ID: 14975502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts.
    Anai S; Goodison S; Shiverick K; Hirao Y; Brown BD; Rosser CJ
    Mol Cancer Ther; 2007 Jan; 6(1):101-11. PubMed ID: 17237270
    [TBL] [Abstract][Full Text] [Related]  

  • 46. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line.
    Joyner DE; Albritton KH; Bastar JD; Randall RL
    J Orthop Res; 2006 Mar; 24(3):474-80. PubMed ID: 16450387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of d-g3139 and its enantiomer L-g3139 in melanoma cells demonstrates minimal in vitro but dramatic in vivo chiral dependency.
    Lai JC; Brown BD; Voskresenskiy AM; Vonhoff S; Klussman S; Tan W; Colombini M; Weeratna R; Miller P; Benimetskaya L; Stein CA
    Mol Ther; 2007 Feb; 15(2):270-8. PubMed ID: 17235304
    [TBL] [Abstract][Full Text] [Related]  

  • 48. G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis.
    Stein CA; Wu S; Voskresenskiy AM; Zhou JF; Shin J; Miller P; Souleimanian N; Benimetskaya L
    Clin Cancer Res; 2009 Apr; 15(8):2797-807. PubMed ID: 19351753
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes.
    Chiu SJ; Liu S; Perrotti D; Marcucci G; Lee RJ
    J Control Release; 2006 May; 112(2):199-207. PubMed ID: 16564596
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
    Lopes de Menezes DE; Mayer LD
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer.
    Tolcher AW
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):67-70. PubMed ID: 11685732
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro.
    Yoo BH; Bochkareva E; Bochkarev A; Mou TC; Gray DM
    Nucleic Acids Res; 2004; 32(6):2008-16. PubMed ID: 15064360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
    Yu B; Mao Y; Bai LY; Herman SE; Wang X; Ramanunni A; Jin Y; Mo X; Cheney C; Chan KK; Jarjoura D; Marcucci G; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
    Blood; 2013 Jan; 121(1):136-47. PubMed ID: 23165478
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma.
    Benimetskaya L; Wittenberger T; Stein CA; Hofmann HP; Weller C; Lai JC; Miller P; Gekeler V
    Clin Cancer Res; 2004 Jun; 10(11):3678-88. PubMed ID: 15173074
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
    Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
    Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy.
    Ko YT; Falcao C; Torchilin VP
    Mol Pharm; 2009; 6(3):971-7. PubMed ID: 19317442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.